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ABSTRACT The membrane protein P-glycoprotein (P-gp) plays
key roles in the oral bioavailability of drugs, their blood brain barrier
passage as well as in multidrug resistance. For new drug candidates it
is mandatory to study their interaction with P-gp, according to FDA
and EMA regulations. The vast majority of these tests are performed
using confluent cell layers of P-gp overexpressing cell lines that render
these tests laborious. In this study, we introduce a cell-free
microfluidic assay for the rapid testing of drug- P-gp interactions.
Cell-derived vesicles are prepared from MDCKII-MDR1 overex-
pressing cells and immobilized on the surface of a planar microfluidic
device. The drug is delivered continuously to the vesicles and calcein
accumulation is monitored bymeans of a fluorescence assay and total
internal reflection fluorescence (TIRF) microscopy. Only small
amounts of compounds (~10 μl) are required in concentrations of
5, 25 and 50 μM for a test that provides within 5 min information on
the apparent dissociation constant of the drug and P-gp. We tested
10 drugs on-chip, 9 of which are inhibitors or substrates of P-
glycoprotein and one negative control. We benchmarked the mea-
sured apparent dissociation constants against an alternative assay on a
plate reader and reference data from FDA. These comparisons
revealed good correlations between the logarithmic apparent disso-
ciation constants (R2=0.95 with ATPase assay, R2=0.93 with FDA
data) and show the reliability of the rapid on-chip test. The herein
presented assay has an excellent screening window factor (Z’-factor)
of 0.8, and is suitable for high-throughput testing.
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INTRODUCTION
P-glycoprotein (P-gp; MDR1; ABCB1) is a member of the
ATP-binding cassette family of transporters with highest
expression in the intestine, liver, kidney and blood brain
barrier (1,2). P-gp actively transports endogenous substrates
such as steroids and cytokines out of the cell (3) and reduces
uptake of xenobiotics into the cell. The transport function
requires energy from ATP hydrolysis whereby ATP
consumption is also significant in the absence of known
substrates. The protein recognizes a broad structural variety
of compounds with generally hydrophobic and basic
properties (4) and is involved in numerous drug-drug interac-
tions (5). It has first been identified as a key player in multi-
drug resistance of cancer cells (6,7). P-gp plays a major role in
the pharmacokinetics of many drugs and drug candidates and
is directly or indirectly involved in reducing absorption,
restricting distribution and increasing excretion of its sub-
strates. The United States Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) both
request the evaluation of drug candidates regarding their P-
gp transport and inhibition and possible drug-drug interac-
tions related to P-gp transport (8).
Several methods are available to test drug- P-gp interac-
tions in vitro, however, the results are often inconsistent (9). The
most widespread assay for in vitro substrate testing for P-gp uses
confluent cell layers grown on a porous membrane. The
concentration of test compounds is measured on one or both
sides of the barrier to evaluate P-gp transport or inhibition.
Other approaches make use of competing cell efflux of a
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fluorescent substrate such as daunomycin, doxorubicin or
rhodamine 123. The calcein AM assay offers an elegant way
to assess P-gp activity (10). Cells are incubated with the non-
fluorescent P-gp substrate calcein AM and accumulation of
the fluorescent calcein, which is the non-permeating product
of enzymatic hydrolysis, is determined. P-gp transport reduces
calcein accumulation. These methods usually involve living
cells and analysis by fluorescence microscopy (10–12), fluores-
cence spectrophotometry (13,14), fluorescence activated cell
sorting (15), or combinations thereof (16). To overcome diffi-
culties associated with cell-based methods, alternative ap-
proaches with artificial membranes were introduced. For ex-
ample, reconstituted P-gp in membranes or P-gp containing
membrane rafts were used to study the potential of a test
compound to alter the ATP consumption of P-gp (17,18).
Recently, Sasaki et al. (19) succeeded to assess P-gp inhibition
in single, inside-out proteoliposomes consisting of membranes
of P-gp transfected Sf9 insect cells. The proteoliposomes were
immobilized in a microfluidic device using DNA duplexes, and
the transport of a fluorescent substrate (rhodamine 123) into
individual vesicles was observed in the presence of inhibitors
after an incubation time of 20 min. Another rapid method with
reconstituted P-gp into liposomes was presented by Melchior
et al. (20). However, reconstitution of P-gp suffers a major draw-
back since it has been shown that the lipid environment influ-
ences the activity of P-gp (21–23), and therefore a natural lipid
environment would provide, in our opinion, more reliable re-
sults. This is further supported by a study that reports synergistic
binding effects of lipids, nucleotides and drugs to P-gp (24).
In this study, we introduce a new method for rapid deter-
mination of drug- P-gp interactions. We use cell-derived ves-
icles obtained from human P-gp overexpressing canine kidney
epithelial cells (MDCK) so that the natural lipid environment
of P-gp is conserved. Unlike cells, these vesicles do not require
cell-culture conditions and are not prone to processes involved
in apoptosis or cell death when exposed to cytotoxic
compounds. We show that these vesicles can be conveniently
prepared in large batches and stored for at least 8 weeks
without significant loss of activity. The vesicles are
immobilized on the surface of a microfluidic channel via a
cholesterol linker (25) and exposed to small volumes of test
compound solution (Fig. 1, SI Figure 1). Estimation of the
apparent transporter-drug dissociation constant (K) is possible
within the short time of 5 min by quantifying the efflux of
calcein AM in the presence and absence of test compound.
MATERIALS AND METHODS
Materials
SU-8 and developers for the resists were purchased from
Microchem (Newton, MA, USA). AZ-9260 and AZ-400K
developer concentrate were obtained from Microchemicals
(Ulm, Germany) . 1H,1H,2H,2H-perf luorodecyl -
dimethylchlorosilane was obtained from ABCR (Karlsruhe,
Germany), and poly(dimethylsiloxane) (PDMS, Sylgard 184)
from Dow Corning (Midland, MI, USA). Streptavidin-Texas
Red conjugate, calcein AM, Dulbecco’s Modified Eagle Me-
dium (DMEM), geneticin sulfate (G418), Glutamax, Hank’s
buffer salt solution (HBSS), Pen/Strep, fetal calf serum (FCS),
phosphate buffered saline (PBS) and Trypsin-EDTA were all
obtained from Life Technologies Europe (Zug, Switzerland).
Avidin and phosphoenolpyruvate (PEP) were obtained from
AppliChem (Gatersleben, Germany). Hexamethyldisilazane
was obtained from MERCK (Zug, Switzerland). Adenosine
triphosphate (ATP), bovine serum albumin (BSA), biotinylat-
ed BSA (bBSA), cytochalasin B, cyclosporine A, elacridar,
ergotamine tartrate, lactate dehydrogenase (LD), loperamide
hydrochloride (HCl), beta-nicotinamide adenine dinucleotide
reduced dipotassium salt (NADH), propranolol HCl, pyruvate
kinase (PK), quinidine HCl, ritonavir HCl, reserpin HCl and
verapamil HCl were all obtained from Sigma-Aldrich (Buchs,
Switzerland). Dimethylsulfoxide (DMSO) was from Chemie
Brunschwig AG (Basel, Switzerland). Erythromycin, ethylene-
diaminetetraacetic acid (EDTA), hydrochloric acid 37%, su-
crose and Triton X-100 were obtained from Fluka.
Coomassie Brilliant Blue G-250, tris(hydroxymethyl)
aminomethane (TRIS) and Tween 20 were obtained from
BIORAD (Richmond, CA, USA). Cholesterol-PEG-biotin
linker (Mw 3,400 Da) was obtained from Nanocs Inc. (Boston,
MA, USA).
Master and Chip Fabrication
For the fabrication of the master mold and the microfluidic
chips, as well as the immobilization protocol, please refer to
the Supporting Information. The microfluidic device is shown
in SI Figure 1.
Raft Preparation and ATPase Assay
MDCKII-MDR1 cells, provided by the Netherlands Cancer
Institute, were cultured as described in reference (26). Raft
extraction and ATPase assay were performed following a
slightly modified protocol from Bucher et al. (18). Due to the
higher expression levels of P-gp in MDCK-MDR1 cells than
in P388/ADR, rafts corresponding to 1 μg protein per well
were used instead of 5 μg.
In this assay, ATP hydrolysis results in equimolar NADH
oxidation via an enzymatic cascade. ATPase activity was
quantified from the decrease in NADH fluorescence with a
Synergy HT plate reader (BioTek, Winooski, VT) (18). For
data analysis, blank samples served as a background, reflecting
the decrease in NADH fluorescence in the presence of rafts
but without addition of ATP and drug (vblank, spontaneous
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oxidation and bleaching of NADH in fluorescence units per
time interval). The basal ATPase activity (v(x=0)) was deter-
mined after ATP addition but in the absence of drug, where x
is the drug concentration. For data analysis, fluorescence
decrease was fitted with a linear regression model between 1
and 2 h after starting the reaction (SI Figure 2a). The obtained
slopes (v(x)) were first background corrected by subtraction of
the slopes from blank samples, and further normalized to the
basal activity (Eq. 1). The resulting data was fitted as a func-
tion of the drug concentration to a transformation of the
Michaelis-Menten Eq. (2):
vapp ¼ v xð Þ–vblankð Þ= v x ¼ 0ð Þ−vblankð Þ ð1Þ
vapp ¼ C þ v0= 1þ K =xð Þ ð2Þ
where v’ denotes the hypothetical maximal relative drug-
induced increase in ATP hydrolysis (assuming no inhibition
at high concentrations, see below) and K is the apparent
dissociation constant (i.e. the drug concentration at half max-
imal increase in ATP hydrolysis). The relative basal activity C
was set to 1, v’ and K were fitted with Eq. 2 and K was used for
further analyses. For drugs with a bell-shaped vapp-x profile (see
SI Figure 3 for examples), concentrations above maximal vapp
were excluded from the fit.
Membrane Vesicle Preparation
Themembrane vesicles were prepared as previously described
by Pick et al. (27). For vesiculation, MDCKII-MDR1 cells
were grown to about 80% confluence. The cell layer was
washed with serum-free RPMI and 10 μg/ml cytochalasin B
in serum-free RPMI was added to induce vesiculation. After
15 min incubation at 37°C, the flask was tapped and the
supernatant was collected. The supernatant, containing the
shed vesicles, was subsequently extruded 11 times (Micro-
Extruder, Avanti Polar Lipids, Alabaster AL) through a poly-
carbonate membrane with 400 nm pore size (Whatmann
Nucleopore, UK). The average diameter of the vesicles was
estimated before and after extrusion by dynamic light scatter-
ing (DLS; Zetasizer 3000 HAS, Malvern Instruments, UK).
Fig. 1 Scheme of the method and the assay. (a) Vesicle preparation. Living cells are incubated with cytochalasin B, resulting in the budding of vesicles from the cell
membrane and encapsulation of intracellular compounds. Important for the fluorescence assay is the encapsulation of the esterases. The vesicles are collected,
extruded and subsequently immobilized on the microfluidic chip via a cholesterol-biotin linker. (b) Fluorescence assay. Left: Addition of calcein AM and ATP to the
cell-derived vesicles. P-gp hinders the permeation of the substrate calcein AM. Under these conditions, no fluorescent calcein is formed in the vesicle. Middle:
Addition of calcein AMwithout ATP results in permeation of calcein AM due to non-functional P-gp. This further leads to the formation of fluorescent calcein inside
the vesicles. Right: Addition of calcein AM, ATP and an additional P-gp substrate. Here, calcein AM partially permeates the membrane, and is partially effluxed by P-
gp. The increase of fluorescent calcein inside the vesicle depends on the extent of drug- P-gp interaction.
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Total protein amount of three individual vesicle preparations
(25 cm2 flasks, 1 ml vesicle preparation) was found to be 9.1,
6.7 and 8.8 μg BSA equivalent respectively, measured by
Bradford assay.
Calcein AM Plate Reader Assay to Optimize Vesicle
Storage Conditions
A fluorescence assay was performed to test the P-gp activity of
cell-derived vesicles after storage. Fresh and stored vesicle
suspensions, respectively, were diluted 1:250 in assay buffer
(HBSS with 30 mMTris HCl and 0.1% (w/v) BSA) and 10 μl
of the dilutions were pipetted into a 96 well plate and further
diluted with 70 μl assay buffer. ATP was added in different
concentrations in 20 μl assay buffer and plate reader mea-
surements were started immediately after addition of 100 μl of
2 μM calcein AM in assay buffer (final concentration 1 μM) in
a Synergy HT plate reader (BioTek, Winooski, VT) for two
hours at 37°C. The excitation and emission wavelengths were
485 and 525 nm, respectively. Duplicates were measured for
each storage condition.
Fluorescence increase over time (v(x)), i.e., calcein accumu-
lation within the vesicles at different ATP concentrations x,
were fitted linearly between 10 and 20 min, and data was
normalized to the slope without added ATP (v(x=0), no efflux
of calcein AM by P-gp) of each preparation and day (Eq. 3, SI
Figure 2b).
vapp ¼ v xð Þ=v x ¼ 0ð Þ ð3Þ
Equation (2) was used to fit the data, with C=1. Here, v’
denotes the calcein accumulation at infinite ATP concentra-
tion (x→∞) and was used for comparisons of the preparations.
Values of v’ <1 indicate functional P-gp while v’ is 1 in the
absence of P-gp transport.
On-Chip Calcein AM Assay
For TIRF experiments, we mounted the chip on the stage of
an inverted microscope (DMI6000B, Leica Microsystems,
Switzerland) equipped with a 100×oil immersion objective
(NA 1.47, HCX Plan Apo, Leica Microsystems, Switzerland).
The control layer was connected to the nitrogen gas houseline
using a custom-built pressure control system and pressurized
up to 3 bar to close the valves. The fluid layer was connected
to a commercial pressure control system (Fluigent, Paris,
France) via Teflon tubing and filled with 10–20 μl buffered
solution or vesicle suspension.
One of the four inlets was filled with a solution containing
2 μM calcein AM in Tris 150 mM pH 7.4. This line served as
a standard for normalization, as well as positive control for
successful surface modification. The other three tubings and
inlets were filled with a solution containing 2 μM calcein AM,
1 mM ATP and the various drug concentrations in 150 mM
Tris pH 7.4.
Initial alignment of the microchip was done with a 561 nm-
laser. For measurements, the 488 nm laser line was used at a
low laser power (15% power according to the Leica LAS AF
control software). The four channels were flushed simulta-
neously by opening the valves (total flow rate of about
1.5 μl/min). Image recording was started directly after open-
ing the valves. The fluorescence emitted from calcein inside
the native vesicles was recorded using a front-illuminated
EMCCD camera (iXon Andor, Belfast, UK) with an
exposure time of 400 ms and a gain of 100. Images were
taken every 10 s for 5 min.
The image processing software ImageJ (28) was used to
determine the fluorescence intensity within one of the four
defined areas just after the four inlet channels were merging
together (see Fig. 3a, SI Figure 1a and b). This allowed
analysis of four conditions, e.g., four drug concentrations in
parallel under otherwise identical conditions. The data from
the first 6 frames was discarded to account for the time that is
required to flush the test solutions to the observation area. The
slope from the calcein AM standard line (v(x=0)) served as
normalization to reduce chip-to-chip variability (Eq. 4, SI
Figure 2c). Here, x denotes the drug concentration in the
different solutions.
vapp ¼ v xð Þ=v x ¼ 0ð Þ ð4Þ
In analogy to the calcein AM assay to optimize storage
conditions, fluorescence increase is inversely linked to P-gp
inhibition (Fig. 1b), i.e. a fully functional P-gp would result in
no fluorescence increase, whereas an inhibited transport func-
tion would result in a characteristic increase in fluorescence. In
this context, vapp=0 (no fluorescence increase) would refer to a
fully functional, non-inhibited P-gp, whereas vapp=1 (maximal
fluorescence increase) would refer to a fully inhibited P-gp.
To obtain the apparent dissociation constant K, the
resulting normalized slopes vapp were plotted against the drug
concentration and the curves were fitted according to Eq. 2. In
this assay, C (here 0.02) is the minimal increase in the absence
of drug but in the presence of calcein AM and ATP, and v’ the
maximal increase at infinite drug concentration (v’=1).
RESULTS
The principle of our new cell-free assay to study drug- P-gp
interactions is shown in Fig. 1. The assay relies on the well-
characterized interaction between the substrate calcein AM
and P-gp (9,13,15,29). In the following, we describe the
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characterization of the cell-derived vesicles, the procedure of
the microfluidic assay, and the comparison of the data with an
alternative assay that measures ATP hydrolysis and with ref-
erence data provided by the FDA.
Vesicle Characterization
Cell-derived vesicles were prepared according to existing pro-
tocols (27,30) and as described in the Materials and Methods
section. The exposure of the cells to cytochalasin B that
interacts with the actin filaments resulted in budding of the
plasma membrane (Fig. 1a). Average diameters of the shed
vesicles ranged from 600 to 1,000 nm, in good agreement with
former studies (27). Extrusion reduced the average diameter
to 150–230 nm with a polydispersity index between 0.5 and
0.7. This size is ideal for observations with a TIRF micro-
scope. Figure 2a shows the dose–response curve of calcein
fluorescence increase for the well-characterized P-gp substrate
verapamil, confirming that both P-gp and esterases are active
after vesicle preparation and extrusion.
To confirm that P-gp transport rather than calcein AM
hydrolysis is rate-limiting in the assay, calcein fluorescence was
measured at various ATP concentrations in a plate reader
format. The results are shown in Fig. 2c. They not only
confirm the presence of active P-gp and of intravesicular
esterases, but also indicate that transport by P-gp is rate-
limiting as fluorescence was strongly dependent on the ATP
concentration. Fluorescence changes were ATP-independent
after lysis of the vesicles.
Influence of Storage Conditions on Vesicle Size
and Activity via a Plate Reader Assay
One advantage of using vesicles compared to cells is the
possibility to freeze vesicles for storage with minimum loss of
activity (27). We tested various storage conditions (Fig. 2b).
After thawing, we determined the diameter of the vesicles by
DLS. As shown in Fig. 2b, the vesicle size distribution did not
significantly change after one day storage under four of the
five tested conditions, including shock freezing in liquid nitro-
gen after addition of 10% DMSO and storage at −80°C.
Shock freezing in the absence of DMSO resulted in broaden-
ing of the size distribution. DLS results of the single batches
did not significantly change after 2, 4 and 8 weeks storage
(data not shown).
The integrity of the vesicles and activity of P-gp and ester-
ases were tested with the calcein AM assay and compared to
the results shown in Fig. 2c for the fresh vesicles and for lysed
vesicles. The value of v’ was 0 for the freshly prepared vesicles
(Eq. 2), i.e. there was no fluorescence increase at high (infinite)
ATP concentration. If the vesicles were lysed, the fluorescence
increase was independent of the concentration of added ATP
and after normalization v’ was approximately 1. Therefore, a
value close to 0 for v’ reflects a good freezing protocol with low
loss in P-gp activity.
Figure 2d shows the fitted values for v’ for all the prepara-
tions tested. Interestingly, preparations 2 and 5 lacking
DMSO as cryoprotectant showed negative v’ values. This
may indicate that the vesicles are leaky and ATP can freely
diffuse over the membrane, i.e. resulting in a higher
intravesicular ATP concentration. Preparations including
DMSO (1, 3 and 4) were less affected by the freezing. For
the following experiments, we used freezing in liquid nitrogen
with added 10% DMSO and subsequent storage at −20°C
(preparation 4) that best preserved the P-gp activity.
Validation of the Microfluidic Calcein AM Assay
The cell-derived vesicles were immobilized by adsorbed bio-
tinylated BSA, an avidin linker and a cholesterol-PEG-biotin
moiety (Mw 3,400 Da, Nanocs Inc.), which tethers the vesicles
without disturbing the domain of the membrane facing to-
wards the fluid (25,31). Next, all valves of the device were
closed and the test solutions were added to the respective
fluidic channels. In the current microchip design, up to 4
different solutions can be introduced and measured at the
same time (Fig. 3a, see also SI Figure 1a and b). In our
experiments, we used 3 inlets for the introduction of test
solutions (different drugs or different concentrations),
and one was used for the introduction of the internal
standard (here 2 μM calcein AM in the absence of both
drug and ATP). The standard gives the maximum fluo-
rescence increase and was used for normalization of the
signals.
Figure 3c shows the raw data traces for an experiment with
two different concentrations (25 and 50 μM) of verapamil at
1 mM ATP. With no verapamil present, no increase in
fluorescence was observed. Addition of verapamil resulted in
increasing fluorescence intensity over time, depending on the
concentration. For further data analysis, the linearly fitted
slopes were normalized to the internal standard that
contained neither drug nor ATP (Eq. 4), and showed the
maximum increase in fluorescence due to non-hindered per-
meation of calcein AM.
Several controls were performed to assure the data quality
and assay conditions. To optimize the ATP concentration, we
investigated the influence of the added ATP concentration on
the amount of permeating calcein AM (Fig. 3b). Formation of
calcein was inversely correlated to ATP concentration, show-
ing that also on-chip P-gp transport was controlling the kinet-
ics of calcein accumulation. For all further microchip experi-
ments, a concentration of 1 mM ATP was chosen.
Next, we determined the spontaneous, enzyme-
independent hydrolysis rate of the calcein AM ester in
buffer with and without added drug. At 60 min after
the preparation of the calcein AM solution, 0.8% of the
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ester was hydrolyzed, independent of the absence or
presence of drug (data not shown). Therefore, we as-
sume that enzyme-independent hydrolysis is negligible
for the microchip experiments.
Additionally, we evaluated the influence of the flow
rate on the signal increase. According to Glaser (32),
who modeled the binding kinetics of a ligand to an
immobilized antibody inside a flow channel, the rela-
tionship between flow rate and signal should be linear
in a mass-transfer limited system. Indeed, we found that
the fluorescence increase is dependent on the flow rate
(Fig. 3d), and we used a constant flow rate of 1.5 μl/
min in all experiments.
Lastly, we investigated the influence of DMSO on the test
system since DMSO is known to enhance the permeation of
solutes across the cellular membrane (33). Permeation rates of
calcein AM were enhanced at higher concentrations of
DMSO (see SI Figure 1c). Therefore, we used a constant
concentration of 0.5% (v/v) DMSO in all subsequent
microfluidic assays.
Determination of Drug- P-gp Interactions
with the Microfluidic Assay
After the control experiments were performed, we tested 9
different substrates/inhibitors of P-gp at various
Fig. 2 Vesicle characterization. (a) Dose–response curve of fresh cell-derived vesicles depending on verapamil concentration measured with a plate reader.
Addition of more verapamil results in a higher increase of fluorescence, due to the less efficient efflux of calcein AM. (b) Size distribution of the vesicles after
extrusion and after one day of storage, measured by dynamic light scattering. Indicated are the freezing procedure, storage temperature and additives. (c) The
fluorescence increase of calcein depends on the amount of added ATP (squares). Measurements were conducted using a plate reader. If P-gp or the esterases are
non-functional after freezing and thawing or the vesicles are ruptured, the ATP dependency of the fluorescent increase (i.e. the calcein AM transport) is partially or
fully lost. This is shown for lysed vesicles (circles). The data was fitted with Eq. 2 to extract v' (blue arrow) for all preparation conditions, which equals the remaining
fluorescence increase at an infinite ATP concentration. Fully functional vesicles have a value of v' = 0; i.e. no fluorescence increase at infinite ATP concentrations,
and deviations indicate deterioration. (d) Comparison of the different preparations after various storage times, measured with a plate reader. The vesicles are
evaluated by means of the ATP-dependent calcein AM transport depicted in (c). Dashed lines show the standard deviation of freshly prepared vesicles. Colors refer
to the same preparations as in (b).
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concentrations in the microfluidic calcein AM assay. Each
measurement was performed three times (SI Figure 4).
As expected, every substrate or inhibitor that we
tested showed an increased fluorescence at higher con-
centrations. For stronger inhibitors such as cyclosporine
A and elacridar, we observed full inhibition at higher
concentrations (for values, please refer to SI Table 1), as
well as a strong inhibition of P-gp at lower concentra-
tions. When comparing these strong inhibitors with
weaker inhibitors such as verapamil or ritonavir, a dif-
ference is seen in the profile. Even at the highest con-
centrations (50 μM) weaker inhibitors were not able to
fully inhibit P-gp. P-gp substrates such as propranolol or
ergotamine showed even less inhibition at the highest
concentration, but still a significantly different profile
than the negative control. As a negative control we
tested geneticin, a hydrophilic basic compound, which
shows no interaction with P-gp (34). Indeed, we found
very low increases in calcein fluorescence when intro-
ducing this substance to the vesicles, presumably
resulting from the added DMSO.
From these data sets, we derived the apparent dissociation
constants K (Eq. 2, curves and fits are shown in SI Figure 4).
The results are shown in Fig. 4.
Determination of Drug- P-gp Interactions
with the ATPase Assay
In parallel to the microfluidic approach, we performed an
ATPase assay for comparison. It makes use of the ATPase
activity of P-gp (35) that is altered in the presence of drugs
interacting with P-gp. In the assay, generated ADP is convert-
ed back to ATP in an enzymatic cascade, leading to the
conversion of fluorescent NADH to non-fluorescent NAD+
(18). NADH oxidation therefore reflects ATPase activity,
which in turn correlates to the transport function.
The measured profile strongly depended on the test sub-
strate (SI Figure 3). Some substrates and inhibitors enhanced
ATP hydrolysis (such as quinidine and elacridar), some
showed a bell-shaped profile (ergotamine and verapamil),
and other drugs showed a decrease in ATPase activity com-
pared to the basal activity (such as cyclosporine A, loperamide,
reserpine, erythromycin and ritonavir). These findings are
consistent with existing literature (18,36). Decreased activity
may result from strong binding of the drug to the P-gp in the
raft, resulting in an inhibition of the basal ATPase activity,
and/or an inefficient transport of the drug through P-gp. The
observation of bell-shaped curves with inhibition at higher
concentrations may result from the accumulation of the drug
Fig. 3 On-chip measurements. (a)
Fluorescent micrograph of the
microfluidic channel at the
measurement region (white square).
The four inlets are filled with
fluorescein of different
concentrations for visualization of
the laminar flow regime. (b) ATP
dependence of the P-gp transport.
Calcein AM can permeate at low
ATP concentrations (high
fluorescence increase) and its
permeation is hindered by P-gp at
high ATP concentrations (Compare
to Fig. 2c for suspended vesicles).
(c) Raw data traces obtained after
supply of calcein AM solution with
and without ATP and addition of the
P-gp substrate verapamil at different
concentrations. At time point zero,
the valves were opened and the
solutions applied to the immobilized
vesicles. (d) Flow rate dependency
of the fluorescence increase in the
vesicles for three conditions. Linear
fits are shown as red lines.
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inside the lipid bilayer of the rafts, thereby disrupting the lipid
order and inhibiting the functionality of the protein. As neg-
ative control, we used geneticin, a drug which does not inter-
act with P-gp (34). As expected, the activity-concentration
profile shows a flat line, meaning that ATP hydrolysis was
not altered at any of the tested concentrations. The resulting
data was fitted with Eq. 2 and the results are shown in Fig. 4.
Comparisons Between FDA, ATPase and on-Chip Data
Next, we compare the results from the ATPase assay and the
on-chip experiments. Figure 4 shows the good linear correla-
tion between K values determined by the microfluidic on-chip
approach and obtained with the ATPase assay in the plate
reader (Eq. 5, slope A=19.40±0.67, y-intercept C=0, R2=
0.98). The absolute values of K differed by a factor of 20 that
will be discussed below.
K on−chip ¼ A K ATPase assay þ C ð5Þ
Furthermore, the extracted apparent dissociation constants
of the microfluidic approach and the ATPase assay show the
same general trend of the dissociation constants as the data
available from the FDA (37), underlining the reliability of both
methods (R2=0.93 for on-chip, R2=0.95 for ATPase assay
for the logarithmic values).
Fast Assessment of the Apparent Dissociation
Constants
The on-chip system may be suited for high throughput deter-
mination of the potency of a drug or drug candidate to
interact with P-gp. As shown above, we found a good corre-
lation between the results of the on-chip and ATPase assay
(Fig. 4). Comparing the normalized fitted slopes (vapp) at a
defined concentration of the test compounds versus K
of the ATPase assay in a semi-log plot followed a
dose–response like behavior for all three tested concen-
trations (SI Figure 5a). As expected from the correlation
in Fig. 4, the half maximal slope on-chip (meaning the
indicated concentration on-chip would equal K on-chip)
corresponded to K of the ATPase assay at 20-fold lower
concentration than on-chip. The fitting parameters of
the dose–response curves are shown in SI Table 2.
To demonstrate the use of the system, we tested the model
compound doxorubicin at three different concentrations (5,
25 and 50 μM) to determine the apparent dissociation con-
stant of the doxorubicin- P-gp interaction. First, we fitted the
on-chip slopes with Eq. 2 (SI Figure 5b). This revealed a K
value of 14.40±5.64 μM.Next, we used the offline calibration
from the ATPase assay for the determination of the respective
K in the ATPase assay (SI Figure 5a and fit parameters in SI
Table 2). We found a good agreement between the calculated
K values for all three different concentrations (SI Figure 5c,
0.76±0.31, 0.35±0.01 and 1.10±0.04 for 50, 25 and 5 μM
respectively). The mean apparent dissociation constant of the
doxorubicin- P-gp interaction estimated for the ATPase assay
according to the correlations in SI Figure 5b was 0.73±
0.35 μM. The advantage of using the ATPase assay for
calibration is that a single point determination at a specific
concentration is enough to estimate the K value, therefore
allowing much higher throughput.
DISCUSSION
In our assay, we combine the use of immobilized P-
glycoprotein overexpressing cell-derived vesicles with
microfluidics. By using cytochalasin B for the production of
cell-derived vesicles, only vesicles from the plasma membrane
Fig. 4 Correlation between K values measured by ATPase assay and fitted values from the on-chip rates. The relation follows a linear trend.
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are formed, with a high proportion of P-gp in the vesicles.
Competing processes involving transporter proteins present in
other cell compartments are reduced, so that a high and
specific drug- P-gp interaction is obtained. Furthermore, the
vesicles contain cytoplasmatic esterases (27), which are re-
quired in the assay presented here.
The use of vesicles instead of cells offers several advantages.
Vesicles can be produced and stored over longer time periods,
retaining their functionality. The monitoring of cell health
during the experiment is not required. This is of particular
interest when testing cytotoxic compounds. Furthermore, in
combination with the microfluidic platform, only small
amounts of test compound (10–20 μL in μM concentrations)
and vesicle solution are needed. Small sample volumes and
the possibility to store the cell-derived vesicles makes it possi-
ble to produce a large batch of vesicles once and use it for
many experiments, therefore reducing heterogeneities that
could occur during cultivation of cells. In contrast to plate
reader formats, it is not required to determine the actual
concentration of the vesicles, as long as the surface of the
device is fully covered by vesicles. Small deviations of the
individual vesicle diameter within a preparation, P-gp density,
or concentration of the esterases are also not influencing the
results as the observation area covers many (ca. 50,000)
immobilized vesicles and the fluorescence intensities are there-
fore averages. Lastly, the natural lipid environment present in
the cell-derived vesicles is beneficial for P-gp studies since it
mimics physiological conditions. However, small alterations in
the cholesterol concentrations are inserted due to the immo-
bilization of the vesicles. Upon immobilization, the increase in
cholesterol content in the outer leaflet over the whole vesicle
can be estimated to be 0.36, and locally 4.20% (see calculation
in the SI). We think that these increases are minor deviations
from the natural composition, and their influence can be
neglected.
By using TIRF microscopy, a gain in sensitivity and spec-
ificity is achieved. Due to the measurements on the surface
where the liposomes are immobilized, the background fluo-
rescence from the channel is reduced, and only fluorophores
inside the vesicles are excited. Optimal is the use of vesicles
with sizes that roughly match the height of the evanescent field
(~200 nm).
The combination with microfluidics provides a con-
stant environment due to the flow, i.e. the concentra-
tions of ATP, drug and calcein AM are constant over
time and are not varying over the measurement period.
This is in contrast to plate reader measurements, where
e.g. the decreasing ATP concentration has to be consid-
ered in data interpretation or compensated during the
measurements. Besides this, the method is also suitable
for plate reader measurements at high throughput using
a suspension of the cell-derived vesicles or surface-
immobilized vesicles and a TIRF microscope.
We used a simple, low-cost microfluidic device made of
PDMS. Because of this, absorption or diffusion of the typically
lipophilic substances into the PDMS have to be considered
(38). To minimize this effect, we used short transport channels
from the inlet to the actual observation position and the
diffusion of molecules from the central channel towards the
walls is negligible within the short residence time of the sub-
stances (300ms at low flow rates of 1.5 μL/min). Additionally,
we selectively measured slightly above the channels glass bot-
tom, where no absorption to PDMS is expected. Therefore,
the concentration of the drug can be considered constant and
equal to the supplied concentration. For more routine appli-
cations, PDMS can easily be exchanged with a material that is
less absorbent, such as glass.
We have demonstrated the use of the system by successfully
correlating the fitted on-chip K values with an ATPase assay
and values given by the FDA. While we always found good
correlations and matching trends, the absolute value of the
apparent dissociation constants differ between the methods.
These variances must be caused by the different experimental
conditions. For example, the FDA measurements were per-
formed with cell monolayers, the ATPase assay used lipid rafts
and the microfluidic device relied on cell-derived vesicles. The
deviation from cell-derived vesicles to cells is minor (factor 2),
and could be assigned to the difference in fluid handling,
different parameters in the assay, and/or interferences with
cellular processes that do not occur in the vesicles. The highest
deviation was found when comparing the two cell-like systems
with the lipid rafts (ATPase assay). Here, other factors could
come into play such as the different lipid environment that
would influence the partitioning of the drugs and therefore the
concentration present at the transporter.
In addition, apparent dissociation constant depends on the
concentration of additional endogenous or added substrates,
such as calcein AM. In our assays, calcein AM was at 1 μM,
this is about 8-fold higher than its reported Michaelis Menten
constant of 0.12 μM for P-gp transport (39). The drug con-
centration at half maximal calcein AM transport is, therefore,
about 10-fold higher in our assay than it would be in the
absence of calcein AM, in analogy to the Cheng-Prussof
equation relating IC50 with absolute Ki values. This could
explain in part the 20-fold higher K values in the calcein AM
than the ATPase assay.
Compounds interacting with P-gp are frequently classified
as substrates, modulators or inhibitors. However, the differ-
entiation between these classifications is not clearly defined
and not used consistently. Several compounds such as verap-
amil or loperamide with low dissociation constants are often
classified as substrates and inhibitors. In these cases, both the K
and the in vivo concentration of the drug must be considered
for evaluation of the effect. Figure 5 depicts a graph showing
the transport activity of P-gp (i.e. vapp) versus the quotient
[drug]/K for all tested compounds and concentrations. Since
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they all follow Michaelis-Menten behavior, the appearance of
the curve is the logical consequence of a saturation experi-
ment. As can be seen, the remaining transport activity of P-gp
is independent of the compound, but dependent on the ratio
of the administered concentration to the dissociation constant.
If [drug]/K >> 1, the compound is inhibiting P-gp, meaning
that there is only small amounts of free P-gp available (i.e. P-
gp is mainly bound to the inhibiting compound). As a result of
this, a P-gp substrate turns to an inhibitor, where it completely
occupies the protein (if supplied in high enough concentra-
tions). The drug can be classified as a substrate if the tested
drug concentration is simular to the dissociation constant
([drug]/K≈1). Furthermore, if [drug]/K<< 1, the drug would
be classified as a non-substrate, even if there would be an
interaction with P-gp observable at higher concentrations.
The relationship between [drug], K and lipoidal (passive)
permeation is shown in SI Figure 6. The data shows the
importance of the concentration used in the assays, and may
help to explain why different drug compounds are classified as
inhibitors, substrates, and/or non-substrates by different as-
says performed by different groups.
Our method enables fast evaluation of the interaction of a
potential drug molecule with the transport protein P-gp and
the here presented assay is, in theory, compatible with high-
throughput measurements. An excellent screening window
factor (Z’-factor) of 0.8 can be calculated for the assay (40).
To further support this hypothesis, we performed an ex-
periment with another substrate, doxorubicin. The whole on-
chip measurements took 15 min (four triplicates each) and
used up 50 μl of each dilution, demonstrating the rapidness
and economic value of the system. After calibration with the
ATPase measurements, a single on-chip determination can be
enough for rapid, but less accurate, assessment of K.Therefore
it would be possible to test up to three different substances at
once, decreasing the measurement time to 5 min and increas-
ing the throughput.
We are also confident that the combination of the
assay with microfluidics has a great potential for high
throughput screening. With modifications of the current
chip design additional benefits could be achieved with
respect to parallelization and further miniaturization
(channels are closed, i.e. no evaporation of the sample).
In future, the device design could be modified with a
microfluidic concentration gradient generator (41) to
introduce many different drug concentrations in parallel
and hence, obtain more data points for the dose–re-
sponse curve. Moreover, different cell-derived vesicles
embedding other membrane transporters or receptors
of interest could be immobilized at different positions
of the channel, so that the interactions of the drug with
these vesicles can be assessed on one single platform
provided that these interactions produce a fluorescent
or bioluminescent readout signal.
CONCLUSION
In conclusion, we have introduced a rapid and economic
method for investigations of drug- P-gp interactions. We were
able to determine K values for various compounds with our
microfluidic system. The results were in good agreement with
an off-chip method (ATPase assay) as well as with FDA data.
The method allows predicting the type of P-gp interaction of
test compounds.
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